The current state-of-the-art in pharmacotherapy for pulmonary sarcoidosis

References

• Statement on sarcoidosis. Am J Respir Crit Care Med. 1999;160(2):736–755. doi: 10.1164/ajrccm.160.2.ats4-99
   PubMed Web of Science ®Google Scholar
• Papanikolaou IC, Antonakis E, Pandi A. State-of-the-art treatments for sarcoidosis. Methodist DeBakey Cardiovasc J. 2022;18(2):94–105. doi: 10.14797/mdcvj.1068
   PubMedGoogle Scholar
• Saketkoo LA, Baughman RP. Biologic therapies in the treatment of sarcoidosis. Expert Rev Clin Immunol. 2016;12(8):817–825. doi: 10.1080/1744666X.2016.1175301
   PubMed Web of Science ®Google Scholar
• Marrades P, Orozco JP, Francesqui J, et al. Current treatment of sarcoidosis. Minerva Respir Med. 2023;62(3):126–134. doi: 10.23736/S2784-8477.23.02063-6
   Google Scholar
• James WE, Baughman R. Treatment of sarcoidosis: grading the evidence. Expert Rev Clin Pharmacol. 2018;11(7):677–687. doi: 10.1080/17512433.2018.1486706
   PubMed Web of Science ®Google Scholar
• Baughman RP, Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Respir Med. 2015;3(10):813–822. doi: 10.1016/S2213-2600(15)00199-X
   PubMed Web of Science ®Google Scholar
• Melani AS, Bigliazzi C, Cimmino FA, et al. A comprehensive review of sarcoidosis treatment for pulmonologists. Pulm Ther. 2021;7(2):325–344. doi: 10.1007/s41030-021-00160-x
   PubMedGoogle Scholar
• Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58(6):2004079. doi: 10.1183/13993003.04079-2020
   PubMed Web of Science ®Google Scholar
• Llabres M, Brito-Zerón P, Ramos-Casals M, et al. Synthetic pharmacotherapy for pulmonary sarcoidosis. Expert Opin Pharmacother. Taylor and Francis Ltd; 2019;20(11):1397–1404. doi: 10.1080/14656566.2019.1615054
   PubMed Web of Science ®Google Scholar
• Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis. JAMA. 2002;287(10):287. doi: 10.1001/jama.287.10.1301
   Web of Science ®Google Scholar
• Grutters JC, van den Bosch JMM. Corticosteroid treatment in sarcoidosis. Eur Respir J. 2006;28:627–636. doi: 10.1183/09031936.06.00105805
   PubMed Web of Science ®Google Scholar
• Gerke AK, Hunninghake G. The immunology of Sarcoidosis. Clin Chest Med. 2008;29(3):379–390. doi: 10.1016/j.ccm.2008.03.014
   PubMed Web of Science ®Google Scholar
• Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a delphi consensus study. Respir Med. 2010;104(5):717–723. doi: 10.1016/j.rmed.2009.12.009
   PubMed Web of Science ®Google Scholar
• Rahaghi FF, Baughman RP, Saketkoo LA, et al. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev. 2020;29(155):190146. doi: 10.1183/16000617.0146-2019
   PubMed Web of Science ®Google Scholar
• Judson M, Barba B, Beegle B, et al. Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des Devel Ther. 2013;325:325. doi: 10.2147/DDDT.S31064
   Google Scholar
• Baughman RP, Judson MA. Relapses of sarcoidosis: what are they and can we predict who will get them? Eur Respir J. 2014;43(2):337–339. doi: 10.1183/09031936.00138913
   PubMed Web of Science ®Google Scholar
• Dhooria S, Sehgal IS, Agarwal R, et al. High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial). Eur Respir J. 2023;62(3):2300198. doi: 10.1183/13993003.00198-2023
   PubMed Web of Science ®Google Scholar
• Vorselaars ADM, Wuyts WA, Vorselaars VMM, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest. 2013;144(3):805–812. doi: 10.1378/chest.12-1728
   PubMed Web of Science ®Google Scholar
• Hagaman JT, Kinder BW, Eckman MH. Thiopurine S-Methyltranferase testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung. 2010;188(2):125–132. doi: 10.1007/s00408-009-9217-8
   PubMed Web of Science ®Google Scholar
• Baughman RP, Meyer KC, Nathanson I, et al. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients. Chest. 2012;142(5):e1–e111. doi: 10.1378/chest.12-1044
   PubMed Web of Science ®Google Scholar
• Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J. 2011;38(5):1145–1150. doi: 10.1183/09031936.00195010
   PubMed Web of Science ®Google Scholar
• Baughman R, Lower Elyse E. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21(1):43–48. doi: 10.1007/s11083-004-5178-y
   PubMed Web of Science ®Google Scholar
• Baughman RP, Nunes H, Sweiss NJ, et al. Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J. 2013;41(6):1424–1438. doi: 10.1183/09031936.00060612
   PubMed Web of Science ®Google Scholar
• Mayovska OV, Rosenstein ED, Kramer N. Nodular sarcoid myositis treated with hydroxychloroquine monotherapy. Cureus. 2023. doi: 10.7759/cureus.41000
   PubMed Web of Science ®Google Scholar
• Davies D, Curwen MP. Chloroquine in the treatment of sarcoidosis. A report from the research committee of the British tuberculosis association. Tubercle. 1967;48(4):257–272. doi: 10.1016/S0041-3879(67)80033-3
   PubMedGoogle Scholar
• Morse SI, Cohn ZA, Hirsch JG, et al. The treatment of sarcoidosis with chloroquine. Am J Med. 1961;30(5):779–784. doi: 10.1016/0002-9343(61)90213-3
   PubMed Web of Science ®Google Scholar
• Belizna C, Meroni PL, Shoenfeld Y, et al. In utero exposure to azathioprine in autoimmune disease. Where do we stand? Autoimmun Rev. 2020;19(9):102525. doi: 10.1016/j.autrev.2020.102525
   PubMed Web of Science ®Google Scholar
• Brill A-K, Ott SR, Geiser T. Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study. Respiration. 2013;86(5):376–383. doi: 10.1159/000345596
   PubMed Web of Science ®Google Scholar
• Papiris S, Stagaki E, Papadaki G, et al. Mycophenolate mofetil as an alternative treatment in sarcoidosis. Pulm Pharmacol Ther. 2019;58:101840. doi: 10.1016/j.pupt.2019.101840
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Noth I, Mirsaeidi M, et al. Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31:46–54.
   PubMed Web of Science ®Google Scholar
• Pariser RJ, Paul J, Hirano S, et al. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765–773. doi: 10.1016/j.jaad.2012.10.056
   PubMed Web of Science ®Google Scholar
• Kamphuis LS, van Zelm MC, Lam KH, et al. Perigranuloma localization and abnormal maturation of B cells. Am J Respir Crit Care Med. 2013;187(4):406–416. doi: 10.1164/rccm.201206-1024OC
   PubMed Web of Science ®Google Scholar
• Sweiss NJ, Lower EE, Mirsaeidi M, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014;43(5):1525–1528. doi: 10.1183/09031936.00224513
   PubMed Web of Science ®Google Scholar
• Thillai M, Atkins CP, Crawshaw A, et al. BTS clinical statement on pulmonary sarcoidosis. Thorax. 2021;76(1):4–20. doi: 10.1136/thoraxjnl-2019-214348
   PubMed Web of Science ®Google Scholar
• Wells AU, Flaherty KR, Brown KK, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8(5):453–460. doi: 10.1016/S2213-2600(20)30036-9
   PubMed Web of Science ®Google Scholar
• Baughman RP, Gupta R, Judson MA, et al. Value of pulmonary function testing identifying progressive pulmonary disease in fibrotic sarcoidosis: results of a prospective feasibility study. Sarcoidosis Vasc Diffuse Lung Dis. 2022;39:e2022011.
   PubMed Web of Science ®Google Scholar
• Culver DA, Aryal S, Barney J, et al. Efzofitimod for the treatment of pulmonary sarcoidosis. Chest. 2023;163(4):881–890. doi: 10.1016/j.chest.2022.10.037
   PubMed Web of Science ®Google Scholar
• Zhou JJ, Wang F, Xu Z, et al. Secreted Histidyl-tRNA Synthetase splice variants elaborate major epitopes for autoantibodies in inflammatory myositis. J Biol Chem. 2014;289(28):19269–19275. doi: 10.1074/jbc.C114.571026
   PubMed Web of Science ®Google Scholar
• Drake WP, Oswald-Richter K, Richmond BW, et al. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis. JAMA Dermatol. 2013;149(9):1040. doi: 10.1001/jamadermatol.2013.4646
   PubMed Web of Science ®Google Scholar
• Baughman RP, Lower EE. Fungal infections as a complication of therapy for sarcoidosis. QJM: An Int J Med. 2005;98(6):451–456. doi: 10.1093/qjmed/hci073
   PubMed Web of Science ®Google Scholar
• Sulica R, Teirstein AS, Kakarla S, et al. Distinctive clinical, radiographic, and functional characteristics of patients with Sarcoidosis-related pulmonary hypertension. Chest. 2005;128(3):1483–1489. doi: 10.1378/chest.128.3.1483
   PubMed Web of Science ®Google Scholar
• Baughman RP, Engel PJ, Nathan S. Pulmonary hypertension in sarcoidosis. Clin Chest Med. 2015;36(4):703–714. doi: 10.1016/j.ccm.2015.08.011
   PubMed Web of Science ®Google Scholar
• Baughman RP, Engel PJ, Taylor L, et al. Survival in sarcoidosis-associated pulmonary hypertension. Chest. 2010;138(5):1078–1085. doi: 10.1378/chest.09-2002
   PubMed Web of Science ®Google Scholar
• Rodman DM, Lindenfeld J. Successful treatment of sarcoidosis-associated pulmonary hypertension with corticosteroids. Chest. 1990;97(2):500–502. doi: 10.1378/chest.97.2.500
   PubMed Web of Science ®Google Scholar
• Mangla A, Fisher J, Libby DM, et al. Sarcoidosis, pulmonary hypertension, and acquired peripheral pulmonary artery stenosis. Cathet Cardiovasc Diagn. 1985;11(1):69–74. doi: 10.1002/ccd.1810110110
   PubMedGoogle Scholar
• Dobarro D, Schreiber BE, Handler C, et al. Clinical characteristics, haemodynamics and treatment of pulmonary hypertension in sarcoidosis in a single centre, and meta-analysis of the published data. Am J Cardiol. 2013;111(2):278–285. doi: 10.1016/j.amjcard.2012.09.031
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay D, Humbert M. An update on sarcoidosis-associated pulmonary hypertension. Curr Opin Pulm Med. 2020;26(5):582–590. doi: 10.1097/MCP.0000000000000701
   PubMed Web of Science ®Google Scholar
• Mathijssen H, Huitema MP, Bakker ALM, et al. Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series. Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(1):74–78. doi: 10.36141/svdld.v37i1.9292
   PubMed Web of Science ®Google Scholar
• Palmero V, Sulica R. Sarcoidosis-associated pulmonary hypertension: assessment and management. Semin Respir Crit Care Med. 2010;31(4):494–500. doi: 10.1055/s-0030-1262217
   PubMed Web of Science ®Google Scholar
• Asif H, Ribeiro Neto M, Culver D. Pulmonary fibrosis in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2023;40(3):e2023027. doi: 10.36141/svdld.v40i3.14830
   PubMed Web of Science ®Google Scholar
• Wijsenbeek MS, Culver DA. Treatment of sarcoidosis. Clin Chest Med. 2015;36(4):751–767. doi: 10.1016/j.ccm.2015.08.015
   PubMed Web of Science ®Google Scholar
• Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med. 2011;183(5):573–581. doi: 10.1164/rccm.201006-0865CI
   PubMed Web of Science ®Google Scholar
• Margaritopoulos GA, Trachalaki A, Wells AU, et al. Pirfenidone improves survival in IPF: results from a real-life study. BMC Pulm Med. 2018;18(1):177. doi: 10.1186/s12890-018-0736-z
   PubMedGoogle Scholar
• Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–1727. doi: 10.1056/NEJMoa1908681
   PubMed Web of Science ®Google Scholar
• Shlobin OA, Nathan SD. Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation. Eur Respir J. 2012;39(6):1520–1533. doi: 10.1183/09031936.00175511
   PubMed Web of Science ®Google Scholar
• Taimeh Z, Hertz MI, Shumway S, et al. Lung transplantation for pulmonary sarcoidosis. Twenty-five years of experience in the USA. Thorax. 2016;71(4):378–379. doi: 10.1136/thoraxjnl-2015-207497
   PubMed Web of Science ®Google Scholar